Meningococcal vaccine group B OMV (NZ) - GlaxoSmithKline/NIPH

Drug Profile

Meningococcal vaccine group B OMV (NZ) - GlaxoSmithKline/NIPH

Alternative Names: MeNZB; New Zealand candidate vaccine (NZ98/254); New Zealand epidemic strain meningococcal B OMV vaccine

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Norwegian Institute of Public Health; Novartis
  • Developer GlaxoSmithKline; Novartis; University Hospitals Bristol NHS Foundation Trust
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Meningococcal group B infections

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 08 Feb 2005 A clinical study has been added to the Bacterial Infections immunogenicity section
  • 11 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections immunogenicity and adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top